BRPI0514911A - seqüências de ácido nucléico codificando proteìnas que têm a capacidade de associar em uma partìcula similar a vìrus - Google Patents

seqüências de ácido nucléico codificando proteìnas que têm a capacidade de associar em uma partìcula similar a vìrus

Info

Publication number
BRPI0514911A
BRPI0514911A BRPI0514911-8A BRPI0514911A BRPI0514911A BR PI0514911 A BRPI0514911 A BR PI0514911A BR PI0514911 A BRPI0514911 A BR PI0514911A BR PI0514911 A BRPI0514911 A BR PI0514911A
Authority
BR
Brazil
Prior art keywords
nucleic acid
virus
associate
particle
ability
Prior art date
Application number
BRPI0514911-8A
Other languages
English (en)
Inventor
Francisco Javier Ortego
Luis Enjuanes Sanches
Juan Plana Duran
Esteban Domingo Solans
Juan Eduardo Ceriani
Original Assignee
Consejo Superior Investigacion
Fort Dodge Veterinaria S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35115899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0514911(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP20040021064 external-priority patent/EP1650308A1/en
Priority claimed from EP04020994A external-priority patent/EP1632247A1/en
Application filed by Consejo Superior Investigacion, Fort Dodge Veterinaria S A filed Critical Consejo Superior Investigacion
Publication of BRPI0514911A publication Critical patent/BRPI0514911A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12323—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SEQüêNCIAS DE áCIDO NUCLéICO CODIFICANDO PROTEìNAS QUE TêM A CAPACIDADE DE ASSOCIAR EM UMA PARTìCULA SIMILAR A VìRUS A presente invenção refere-se a ácidos nucléicos compreendendo: (a) seqüências de um vírus de gastroenterite transmissível competente para replicação (TGEV), cujas seqüências codificam uma TGEV replicase sob o controle de seqüências regulatórias de expressão de modo que a expressão da replicase em uma célula contendo o ácido nucléico iniciará a replicação do ácido nucléico e deste modo aumentará o número de ácidos nucléicos na célula; e (b) seqüências codificando uma ou mais proteínas de um vírus diferente em que a uma ou mais proteínas têm a capacidade de associar em uma partícula similar a vírus (VLP) que não contém qualquer ácido nucléico infeccioso. A presente invenção refere-se adicionalmente a vetores, partículas de vírus e células hospedeiras compreendendo estes ácidos nucléicos bem como sua aplicação para a preparação de vacinas, especificamente para a preparação de vacinas.
BRPI0514911-8A 2004-09-03 2005-09-02 seqüências de ácido nucléico codificando proteìnas que têm a capacidade de associar em uma partìcula similar a vìrus BRPI0514911A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20040021064 EP1650308A1 (en) 2004-09-03 2004-09-03 Nucleic acid sequences encoding proteins capable of associating into a virus-like particle
EP04020994A EP1632247A1 (en) 2004-09-03 2004-09-03 Nucleic acid sequences encoding FMDV proteins capable of associating into a virus-like particle
PCT/EP2005/009477 WO2006024542A1 (en) 2004-09-03 2005-09-02 Nucleic acid sequences encoding proteins capable of associating into a virus-like particle

Publications (1)

Publication Number Publication Date
BRPI0514911A true BRPI0514911A (pt) 2008-06-24

Family

ID=35115899

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514911-8A BRPI0514911A (pt) 2004-09-03 2005-09-02 seqüências de ácido nucléico codificando proteìnas que têm a capacidade de associar em uma partìcula similar a vìrus

Country Status (7)

Country Link
US (1) US20060165723A1 (pt)
EP (2) EP2295590A1 (pt)
AR (1) AR051923A1 (pt)
AU (1) AU2005279303B2 (pt)
BR (1) BRPI0514911A (pt)
CA (1) CA2591532A1 (pt)
WO (1) WO2006024542A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6380376B1 (en) 1992-10-30 2002-04-30 Iowa State University Research Foundation Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
EP1792996A1 (en) * 2005-12-01 2007-06-06 Consejo Superior de Investigaciones Cientificas Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV)
WO2009148964A2 (en) * 2008-05-29 2009-12-10 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Expression and assembly of human group c rotavirus-like particles and uses thereof
US8663951B2 (en) * 2009-01-09 2014-03-04 Academia Sinica Method of producing virus-like particles of picornavirus using a small-ubiquitin-related fusion protein expression system
JP2013509203A (ja) * 2009-11-02 2013-03-14 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 口蹄疫ウイルス（ｆｍｄｖ）コンセンサスタンパク質、そのコード配列およびそれから生成されるワクチン
CN111961655B (zh) * 2015-04-17 2022-08-09 普莱柯生物工程股份有限公司 口蹄疫病毒样颗粒、制备方法、疫苗组合物和应用
KR102165358B1 (ko) * 2017-12-29 2020-10-14 (주)플럼라인생명과학 구제역 바이러스 a형 백신 조성물
CN108864259A (zh) * 2018-07-03 2018-11-23 复旦大学 一种猪圆环病毒2型病毒样颗粒的溶出方法
EP4225361A1 (en) * 2020-10-05 2023-08-16 Boehringer Ingelheim Animal Health USA Inc. Fusion protein comprising circoviridae capsid protein, and chimeric virus-like particles composed thereof
CN113957093B (zh) * 2021-08-26 2022-09-20 中国农业科学院北京畜牧兽医研究所 用于pAPN基因定点修饰的系统及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2109189B1 (es) * 1996-03-14 1998-05-16 Iberica Cyanamid Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas.
ES2170622B1 (es) 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
EP2365082A1 (en) * 2000-06-27 2011-09-14 Pfizer Animal Health S.A. BVDV virus-like particles
US7556957B2 (en) * 2001-05-17 2009-07-07 Stichting Voor De Technische Wetenschappen Coronavirus-like particles comprising functionally deleted genomes
EP1470218B1 (en) * 2001-05-17 2010-07-07 Universiteit Utrecht Corona-virus-like particles comprising functionally deleted genomes
DE60234375D1 (de) * 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG

Also Published As

Publication number Publication date
EP2295590A1 (en) 2011-03-16
AR051923A1 (es) 2007-02-21
AU2005279303B2 (en) 2011-10-27
EP1789566A1 (en) 2007-05-30
AU2005279303A1 (en) 2006-03-09
CA2591532A1 (en) 2006-03-09
WO2006024542A1 (en) 2006-03-09
US20060165723A1 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
Haque et al. Efforts at COVID-19 vaccine development: challenges and successes
BR112015006763B1 (pt) Constructo de ácido nucleico, vetor de transferência plasmídico, partículas de vírus mv-chik, composições, uso da composição, uso das partículas de vírus mv-chik e processo para resgatar vírus do sarampo (mv) recombinante
Whittle et al. Lumpy skin disease—an emerging cattle disease in Europe and Asia
EP2275565A3 (en) Nucleic acids encoding TGEV and PRRSV sequences for improved expression of PRRSV sequences
McBride et al. The coronavirus nucleocapsid is a multifunctional protein
BRPI0514911A (pt) seqüências de ácido nucléico codificando proteìnas que têm a capacidade de associar em uma partìcula similar a vìrus
RU2011128371A (ru) Модифицированные f протеины sv и способы их применения
BRPI1015053A2 (pt) partículas similares a vírus da influenza quiméricas compreendendo hemaglutinina
Burrell et al. Virion structure and composition
BRPI0417509A (pt) molécula de proteìna quimérica de núcleo de vìrus da hepatite b (hbc) recombinante, partìculas, vacina ou inóculo, ácido nucleico, molécula de ácido nucleico recombinante, e, célula hospedeira
BR112020026620A8 (pt) Mutantes de hemaglutinina do vírus influenza
TR201908199T4 (tr) HPV'ye karşı aşılar.
RU2019129680A (ru) Коронавирусы, вакцины с коронавирусами в составе, а также способы предотвращения заболеваний
BR112018075420A2 (pt) melhoramento da imunogenicidade de petídeo l2
Ragan et al. A whole virion vaccine for COVID-19 produced via a novel inactivation method and preliminary demonstration of efficacy in an animal challenge model
Garofalo et al. Prospects of replication-deficient adenovirus based vaccine development against SARS-CoV-2
BR112015006798A2 (pt) vírus da vacínia ankara modificado, genoma, célula, métodos para cultivar um vírus mva, para produzir um vírus mva e para produzir um vírus mva recombinante, composição farmacêutica, vacina, vírus mva ou genoma, e, molécula de ácido nucleico
BR112013004183A2 (pt) plantas com melhores características relacionadas ao rendimento e método para sua produção
Barry et al. Poxvirus exploitation of the ubiquitin-proteasome system
Gallardo et al. Double deletion of EP402R and EP153R in the attenuated Lv17/WB/Rie1 African swine fever virus (ASFV) enhances safety, provides DIVA compatibility, and confers complete protection against a genotype II virulent strain
Xu et al. Development and immunogenicity study of subunit vaccines based on spike proteins of porcine epidemic diarrhea virus and porcine transmissible gastroenteritis virus
RU2010152562A (ru) Векторы экспрессии, кодирующие репликазу альфавируса, и их применение в качестве иммунологического адьюванта
BR112017014160A2 (pt) produção de partículas semelhantes a rotavírus nas plantas
CO5580837A2 (es) Vacuna dna que codifica al menos dos proteinas tempranas no estructurales de papilomavirus
Gokduman et al. Potential of Bovine Herpesvirus Vectors for Recombinant Vaccines

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.